Recommended monitoring for patients receiving pre-exposure prophylaxis for HIV (6), (7)
| Laboratory analysis | Baseline | Q3 months | Q12 months |
|---|---|---|---|
| HIV serology | X | X | |
| Hepatitis A total antibody | X (vaccinate if not immune) | ||
| Hepatitis B screen (surface antigen, surface antibody and core antibody) | X (vaccinate if not immune) | X (if not immune) | |
| Hepatitis C antibody | X | X | |
| Gonorrhea and chlamydia screen (urine, throat swab or rectal swab NAAT depending on type of sexual activity reported) | X | X | |
| Syphilis serology | X | X | |
| Serum creatinine | X | X | |
| Lipid panel (TAF/FTC only) | X | X | |
| Urinalysis | X | ||
| Pregnancy test (as appropriate) | X | X |
Note: NAAT = nucleic acid amplification test, TAF/FTC = tenofovir alafenamide fumarate/emtricitabine.